{"id":9431,"date":"2021-04-27T10:06:33","date_gmt":"2021-04-27T17:06:33","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9431"},"modified":"2021-04-30T10:30:46","modified_gmt":"2021-04-30T17:30:46","slug":"covid-19-literature-situation-report-april-27-2021","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/27\/covid-19-literature-situation-report-april-27-2021\/","title":{"rendered":"COVID-19 Literature Situation Report April 27, 2021"},"content":{"rendered":"<p>The scientific literature on COVID-19 is rapidly evolving and these articles were selected for review based on their relevance to Washington State decision making around COVID-19 response efforts. Included in these Lit Reps are some manuscripts that have been made available online as pre-prints but have not yet undergone peer review. Please be aware of this when reviewing articles included in the Lit Reps.<\/p>\n<p><em>Today&#8217;s summary is based on a review of 299 articles (267 published, 32 in preprint)<\/em><\/p>\n<p><strong><a href=\"https:\/\/depts.washington.edu\/pandemicalliance\/wordpress\/wp-content\/uploads\/2021\/04\/LitRep_20210427.pdf\">View the PDF version here.<\/a><\/strong><\/p>\n<h2>Key Takeaways<\/h2>\n<ul>\n<li><b>The Advisory Committee on Immunization Practices (ACIP) reaffirmed its interim recommendation for use of the Johnson &amp; Johnson COVID-19 vaccine in all persons aged \u226518 years on April 23, 2021, with the addition of a warning that rare clotting events may occur in female vaccine recipients aged 18-49 years. A risk-benefit analysis that guided ACIP recommendations suggested that for every 1 million doses administered to women aged 18-49 years, 297 COVID-19-related hospitalizations, 56 ICU admissions, and 6 deaths could be prevented, compared with 7 expected cases of thrombosis with thrombocytopenia. <\/b><a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7017e4\"><span style=\"font-weight: 400;\">More<\/span><\/a><\/li>\n<li><b><\/b><b>The effectiveness of COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in preventing PCR-confirmed SARS-CoV-2 infection was 96% among 45,000 fully vaccinated US healthcare personnel. Vaccine effectiveness was 78% among those receiving only one dose (n&gt;4,000). <\/b><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab361\"><span style=\"font-weight: 400;\">More<\/span><\/a><\/li>\n<\/ul>\n<div id=\"uw-accordion-shortcode\">\n<h3>Article Summaries<\/h3>\n<div class=\"js-accordion\" data-accordion-prefix-classes=\"uw-accordion-shortcode\">\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400;\">Transmission<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9434\" class=\"su-post\">\n<h5 class=\"su-post-title\">Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">An analysis of SARS-CoV incidence and the rate of test positivity in Israel suggests that children age 0-9 years of age did not have substantially elevated rates of SARS-CoV-2 infection during school attendance. Compared to the period before school reopening, after school reopened in September 2020 there was a 10% increase in SARS-CoV-2 incidence and a 23% decline in test positivity in this age group. Larger increases in incidence and test positivity were observed in other age groups, with up to 3.2-fold higher incidence for those aged 40-59 years. Similar patterns were observed during a second period of school reopening in November 2020 following a country-wide lockdown.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Somekh et al.\u00a0(Apr 26, 2021). Comparison of COVID-19 Incidence Rates Before and After School Reopening in Israel. JAMA Network Open. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7105\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7105<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">T<span style=\"font-weight: 400;\">esting and Treatment<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9438\" class=\"su-post\">\n<h5 class=\"su-post-title\">SARS-Cov2 Infection Detection by Polymerase Chain Reaction and Serologic Testing in Clinical Practice<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A retrospective study found that 7% participants (271 of 3,075) who underwent both PCR and serologic testing had discordant test results (i.e. negative PCR result and seropositive or vice-versa). These participants either sought PCR testing after viral shedding would be expected to have ended (PCR- but seropositive) or sought serology tests before a detectable antibody response would be expected (PCR+ but seronegative). Cycle threshold (Ct) values for PCR tests was positively correlated with days since symptom onset, indicating that viral load decreased with increasing time. However, no relationship was observed between Ct values and antibody titers from serology tests.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Murad et al.\u00a0(Apr 26, 2021). SARS-Cov2 Infection Detection by Polymerase Chain Reaction and Serologic Testing in Clinical Practice. Journal of Clinical Microbiology. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1128\/JCM.00431-21\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1128\/JCM.00431-21<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9436\" class=\"su-post\">\n<h5 class=\"su-post-title\">SARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The implementation of point prevalence survey (PPS) testing for SARS-CoV-2 infections in 34 nursing homes in Connecticut was associated with a 41-80% reduction in the incidence rate in nursing homes. Data were obtained from public health surveillance records beginning 4 weeks prior to widespread implementation of PPS testing on May 2020 and up to 12 weeks after implementation, during which a combined total of 205 PPSs among staff and 232 PPSs testing among residents were conducted. Results were adjusted for decreases in community incidence during the study period.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Ehrlich et al.\u00a0(Apr 20, 2021). SARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA. Emerging Infectious Diseases. <\/span><\/i><a href=\"https:\/\/doi.org\/10.3201\/eid2705.204936\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.3201\/eid2705.204936<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\">Vaccines and Immunity<\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9442\" class=\"su-post\">\n<h5 class=\"su-post-title\">Effectiveness of MRNA COVID-19 Vaccines against SARS-CoV-2 Infection in a Cohort of Healthcare Personnel<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The COVID-19 mRNA vaccines were up to 96% effective in preventing PCR-confirmed SARS-CoV-2 infection following two doses, according a retrospective cohort study of over 45,000 US healthcare personnel. The Pfizer-BioNTech vaccine accounted for 93% of vaccinations and the Moderna vaccine accounted for 7%. The authors adjusted for age, gender, region, job, and week of vaccination in their analysis. Vaccine effectiveness was 78% among those receiving only one dose (n&gt;4,000).<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Swift et al.\u00a0(Apr 26, 2021). Effectiveness of MRNA COVID-19 Vaccines against SARS-CoV-2 Infection in a Cohort of Healthcare Personnel. Clinical Infectious Diseases. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab361\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1093\/cid\/ciab361<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9440\" class=\"su-post\">\n<h5 class=\"su-post-title\">Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients \u2014 United States, April 2021<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The Advisory Committee on Immunization Practices (ACIP) reaffirmed its interim recommendation for use of the Johnson &amp; Johnson vaccine in all persons aged \u226518 years on April 23, 2021 and recommended including a warning that rare clotting events may occur in female vaccine recipients aged 18-49 years. The updated recommendations follow the recommended pause by the FDA and CDC on April 13, 2021 after reports of thrombosis with thrombocytopenia (TTS) among a small number of vaccine recipients, including central venous sinus thrombosis. As of April 21, 2021, 15 reports of TTS have been reported among approximately 8 million Johnson &amp; Johnson vaccine doses.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A risk-benefit analysis model that guided ACIP recommendations suggested that over 6 months, resuming vaccine use among persons aged \u226518 years (at 50% of administration rate before the pause) could prevent 3,926 to 9,395 COVID-19-related hospitalizations, 928 to 2,236 ICU admissions, and 586 to 1,435 deaths compared with 26 expected cases of TTS. For every 1 million doses administered to women aged 18-49 years, 297 COVID-19-related hospitalizations, 56 ICU admissions, and six deaths could be prevented, compared with 7 expected TTS cases.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">MacNeil et al.\u00a0(Apr 27, 2021). Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson &amp; Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients \u2014 United States, April 2021. MMWR. <\/span><\/i><a href=\"https:\/\/doi.org\/10.15585\/mmwr.mm7017e4\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.15585\/mmwr.mm7017e4<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"js-accordion__panel\" >\n<h2 class=\"js-accordion__header\"><span style=\"font-weight: 400;\">Clinical Characteristics and Health Care Setting<\/span><\/h2>\n<div class=\"su-posts su-posts-default-loop\">\n<div id=\"su-post-9452\" class=\"su-post\">\n<h5 class=\"su-post-title\">Fatigue Symptoms Associated with COVID-19 in Convalescent or Recovered COVID-19 Patients a Systematic Review and Meta-Analysis<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Fatigue was more 3.7-fold as common among patients recovering from COVID-19 compared to healthy controls, according to a systematic review of 39 studies (n=8,825 patients). Over half of hospitalized patients reported symptoms of fatigue up to two months after discharge. Female gender was associated with greater self-reported fatigue and self-report of fatigue varied by geographic location, with studies from Europe reporting the highest rates of fatigue.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Rao et al.\u00a0(Apr 26, 2021). Fatigue Symptoms Associated with COVID-19 in Convalescent or Recovered COVID-19 Patients a Systematic Review and Meta-Analysis. Pre-print downloaded Apr 27 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.23.21256006\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.23.21256006<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9450\" class=\"su-post\">\n<h5 class=\"su-post-title\">Risk Factors for Long Covid in Previously Hospitalised Children Using the ISARIC Global Follow-up Protocol A Prospective Cohort Study<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> 24% of children hospitalized with COVID-19 in Moscow, Russia reported persistent symptoms at approximately 1 year post-discharge (n=518; median age 10 years). The most commonly reported symptoms were fatigue, followed by sleep disturbance and sensory problems. Persistent symptoms were more common among those aged 6-18 years compared to patients aged &lt;2 years, as well as among those with allergic diseases.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Osmanov et al.\u00a0(Apr 26, 2021). Risk Factors for Long Covid in Previously Hospitalised Children Using the ISARIC Global Follow-up Protocol A Prospective Cohort Study. Pre-print downloaded Apr 27 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.26.21256110\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.26.21256110<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9448\" class=\"su-post\">\n<h5 class=\"su-post-title\">6-Month Follow Up of 8679 Hospitalized COVID-19 Patients in Germany A Nationwide Cohort Study<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> 180-day mortality was 30% in a large cohort (n=8,679; median age 72 years) from Germany hospitalized with COVID-19 from February to April 2020. 180-day mortality was 52% among patients aged \u226580 years and 53% for patients who had undergone invasive mechanical ventilation. Coagulopathy, BMI \u2265 40, and age were risk factors for 180-day mortality. Overall readmission rate within 180 days of discharge was 27%.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Guenster et al.\u00a0(Apr 26, 2021). 6-Month Follow Up of 8679 Hospitalized COVID-19 Patients in Germany A Nationwide Cohort Study. Pre-print downloaded Apr 27 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.04.24.21256029\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.04.24.21256029<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9446\" class=\"su-post\">\n<h5 class=\"su-post-title\">Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The SARS-CoV-2 D614G variant was associated with increased survival in hospitalized patients (86% vs 59% for other identified variants) according to analysis from a repeated cross-sectional study (n=302) of SARS-CoV-2 isolates from the Cleveland Clinic during the first wave of infection (March to April 2020). While 6 different clades were initially identified in the beginning of the study, clade diversity rapidly decreased with D614G isolates comprising 64% of samples (21 of 33) in week 1 to 93% of samples (28 of 30) by week 6. The authors suggest these findings may help explain decreasing mortality among those hospitalized throughout the pandemic.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Esper et al.\u00a0(Apr 26, 2021). Genomic Epidemiology of SARS-CoV-2 Infection During the Initial Pandemic Wave and Association With Disease Severity. JAMA Network Open. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7746\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7746<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<div id=\"su-post-9444\" class=\"su-post\">\n<h5 class=\"su-post-title\">Impaired Diffusing Capacity for Carbon Monoxide Is Common in Critically Ill Covid-19 Patients at Four Months Post-Discharge<\/h5>\n<p>\t\t\t\t<!-- \n\n\n\n\n\n\n\n\n\n\n\n<div class=\"su-post-meta\">\n\t\t\t\t\t: \t\t\t\t<\/div>\n\n\n\n\n\n\n\n\n\n\n\n --><\/p>\n<div class=\"su-post-excerpt\">\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Impaired lung function was present in 52% of COVID-19 patients four months after discharge from the ICU from March to July 2020 (n=60). The most prevalent impairment was lower than normal diffusing capacity for carbon monoxide (DLCO) (45%). Impaired DLCO was more common among those aged &gt;60 years and those who received invasive mechanical ventilation at the ICU.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Ekbom et al.\u00a0(Apr 9, 2021). Impaired Diffusing Capacity for Carbon Monoxide Is Common in Critically Ill Covid-19 Patients at Four Months Post-Discharge. Respiratory Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.rmed.2021.106394\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.rmed.2021.106394<\/span><\/a><\/p>\n<\/p>\n<\/div>\n<p>\t\t\t\t\t\t\t\t\t<!-- <a href=\"\" class=\"su-post-comments-link\"><\/a> --><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Other Resources and Commentaries<\/h2>\n<ul>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1016\/S2352-3018(21)00070-9\"><span style=\"font-weight: 400;\">Overview of SARS-CoV-2 Infection in Adults Living with HIV<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 The Lancet HIV (May 1)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1093\/cid\/ciab363\"><span style=\"font-weight: 400;\">One in Every Three COVID-19 Reinfections Result in Hospitalization in the US<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Clinical Infectious Diseases (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1186\/s12884-021-03784-8\"><span style=\"font-weight: 400;\">SARS-COV-2 Infection in Pregnant Women and Newborns in a Spanish Cohort (GESNEO-COVID) during the First Wave<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 BMC Pregnancy and Childbirth (Dec 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.3201\/eid2705.210015\"><span style=\"font-weight: 400;\">Introduction of ORF3a-Q57H SARS-CoV-2 Variant Causing Fourth Epidemic Wave of COVID-19, Hong Kong, China<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Emerging Infectious Diseases (May 22)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1080\/1059924X.2021.1913272\"><span style=\"font-weight: 400;\">A Mobile Primary Care Clinic Mitigates an Early COVID-19 Outbreak Among Migrant Farmworkers in Iowa<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Journal of Agromedicine (Apr 27)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1136\/bmjebm-2021-111695\"><span style=\"font-weight: 400;\">Can Shared Decision Making Address COVID-19 Vaccine Hesitancy<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 BMJ Evidence-Based Medicine (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1016\/j.cmi.2021.04.009\"><span style=\"font-weight: 400;\">Disinfectant Effectiveness against SARS-CoV-2 and Influenza Viruses Present on Human Skin: Model-Based Evaluation<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Clinical Microbiology and Infection (Apr 23)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33900934\"><span style=\"font-weight: 400;\">Quantifying the Online News Media Coverage of the COVID-19 Pandemic: Text Mining Study and Resource<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Journal of Medical Internet Research (Apr 18)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1136\/bmj.n1089\"><span style=\"font-weight: 400;\">Covid-19: Wider Use of FFP3 Masks May Be Needed Because of Airborne Transmission, Say Scientific Advisers<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 BMJ (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1001\/jamainternmed.2021.1429\"><span style=\"font-weight: 400;\">Hand Hygiene Compliance Rate During the COVID-19 Pandemic<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 JAMA Internal Medicine (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1016\/j.cmi.2021.04.002\"><span style=\"font-weight: 400;\">Long-Term Outcomes of Patients Following Hospitalization for COVID-19: A Prospective Observational Study<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Clinical Microbiology and Infection (Apr 22)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1002\/jcop.22583\"><span style=\"font-weight: 400;\">Hand Hygiene during the COVID-19 Pandemic among People Experiencing Homelessness\u2014Atlanta, Georgia, 2020<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Journal of Community Psychology (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1007\/s40615-021-01041-4\"><span style=\"font-weight: 400;\">COVID-19 Imperils Access to Health and Human Services in El Paso, Texas and New York City: Perspectives from Hispanic Parents<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 Journal of Racial and Ethnic Health Disparities (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1101\/2021.04.26.21256116\"><span style=\"font-weight: 400;\">Patterns of SARS-CoV-2 Aerosol Spread in Typical Classrooms<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 MedRxiv (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1186\/s12889-021-10816-7\"><span style=\"font-weight: 400;\">Predicting Intention to Receive COVID-19 Vaccine among the General Population Using the Health Belief Model and the Theory of Planned Behavior Model<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 BMC Public Health (Dec 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1016\/S2352-3026(21)00107-1\"><span style=\"font-weight: 400;\">COVID-19 Vaccines: Building and Maintaining Confidence<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 The Lancet Haematology (May 1)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.nap.edu\/catalog\/26154\/understanding-and-communicating-about-covid-19-vaccine-efficacy-effectiveness-and-equity\"><span style=\"font-weight: 400;\">Understanding and Communicating about COVID-19 Vaccine Efficacy, Effectiveness, and Equity<\/span><\/a><span style=\"font-weight: 400;\"> \u2013National Academies of Sciences, Engineering, and Medicine (2021)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1371\/journal.ppat.1009509\"><span style=\"font-weight: 400;\">Individuals Cannot Rely on COVID-19 Herd Immunity: Durable Immunity to Viral Disease Is Limited to Viruses with Obligate Viremic Spread<\/span><\/a><span style=\"font-weight: 400;\"> \u2013 PLOS Pathogens (Apr 26)<\/span><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/doi.org\/10.1016\/j.accpm.2021.100867\"><span style=\"font-weight: 400;\">SARS-CoV-2 Vaccination Efficacy on Hospitalisation and Variants<\/span><\/a><span style=\"font-weight: 400;\"> \u2013<\/span><span style=\"font-weight: 400;\"> Anaesthesia Critical Care &amp; Pain Medicine. (Apr 23)<\/span><span style=\"font-weight: 400;\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400;\">Report prepared by the UW Alliance for Pandemic Preparedness and Global Health Security and the START Center in collaboration with and on behalf of WA DOH COVID-19 Incident Management Team<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Advisory Committee on Immunization Practices (ACIP) reaffirmed its interim recommendation for use of the Johnson &amp; Johnson COVID-19 vaccine in all persons aged \u226518 years on April 23, 2021, with the addition of a warning that rare clotting events may occur in female vaccine recipients aged 18-49 years. A risk-benefit analysis that guided ACIP recommendations suggested that for every 1 million doses administered to women aged 18-49 years, 297 COVID-19-related hospitalizations, 56 ICU admissions, and 6 deaths could be prevented, compared with 7 expected cases of thrombosis with thrombocytopenia. <\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/27\/impaired-diffusing-capacity-for-carbon-monoxide-is-common-in-critically-ill-covid-19-patients-at-four-months-post-discharge\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":9433,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[5],"tags":[],"topic":[],"class_list":["post-9431","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-19-literature-situation-report"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9431"}],"version-history":[{"count":2,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9431\/revisions"}],"predecessor-version":[{"id":9482,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9431\/revisions\/9482"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media\/9433"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9431"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}